Abstract: Camomile oil having a high cis- and trans-spiroether content is produced in a process which includes steam distillation or aqueous distillation of fresh camomile or an extraction residue of camomile.

Abstract: Camomile oil having a high cis- and trans-spiroether content is produced in a process which includes steam distillation or aqueous distillation of fresh camomile or an extraction residue of camomile.

Abstract: Ifosfamide lyophilizate consisting substantially of ifosfamide and 0.1 to 17 parts by weight of a hexitol.

Abstract: Solid oral ifosfamide formulations comprising a capsule containing a mass which consists essentially of the active substance ifosfamide and microcrystalline cellulose, or in the form of tablets which contain, in relation to one part by weight of ifosfamide,0.1-1.0 parts by weight of tribasic calcium phosphate and0.04-0.4 parts by weight of polyethylene glycol as well as in addition, related to the weight of the tablet5-60% by weight of a filling and flow regulating agent1-10% by weight of a disintegrant0.1-10% by weight of an antiadhesion agent and0.1-80% by weight of a binding agent.

Abstract: An ifosfamide-mesna lyophilizate consists substantially of ifosfamide, 0.1-1.0 parts by weight of mesna and 0.1 to 17 parts by weight of hexitol. The product is obtained by freeze drying an aqueous or aqueous-ethanolic solution of ifosfamide and mesna.

Abstract: Improved camomile extracts are obtained by extraction of fresh camomile flowers with aqueous lower alkanols and wthout a subsequent heat treatment.

Abstract: This invention relates to the production of camomile extracts rich in flavone by extracting ordinary camomile drug together with added camomile wing petals.

Abstract: There is provided a process for the recovery of pure hellebrin which comprises extracting a defatted hellebrin extract dissolved in a water-alkanol mixture or water-acetone mixture with a mixture of a lower alkanol or acetone and di-, tri-, or tetrachloromethane (or dichloroethane) evaporating the extraction agent in a vacuum and then heating with ethanol until the deposition of the first hellebrin crystals begins.

Abstract: There are prepared compounds corresponding to the general formula: ##STR1## in which R represents a 2,2-dimethylethenyl; isopropyl; nonyl; a C.sub.3 -C.sub.6 -cycloalkyl radical; a phenyl group substituted by at least one nitro group, or a C.sub.1 -C.sub.6 -alkyl group containing a morpholine group attached thereto, said morpholine ring being substituted zero to twice by C.sub.1 -C.sub.6 -alkyl groups; R.sub.3 is --CHO or --CH.sub.2 OH, their optically active forms and their salts. The compounds have cardioactivity e.g., bradycardic effect and have local anethetic, spasmolytic and antiarythmic activity.

Abstract: Compounds are prepared of the formula ##STR1## The compounds of the invention possess valuable pharmacodynamic properties. They especially have a positive inotropic effect which is particularly noted in oral or enteral application. In contrast to the known compounds the compounds of the invention have more favorable pharmacological or pharmaceutical properties.

Abstract: The main sapogenins in the roots and rhizomes of Helleborous species are recovered by treating the roots and/or rhizomes or drugs or extracts made therefrom with cellulase, hemicellulase or .beta.-glucosidase.

Abstract: The main sapogenin of the roots and rhizomes of Helleborus species is used in medicine, especially to treat ulcers.

Abstract: .alpha.- Bisabolol of plant origin is purified by being treated with alkali hydroxide, alkali alcoholate, alkali carbonate, alkali bicarbonate, alkaline earth hydroxide, alkaline earth oxide or aluminium hydroxide. Preferably activated carbon is also used in the purification. Preferably the .alpha.-bisabolol is treated with pure nitrogen gas before the alkali treatment.